Retraction
The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer
Paper Information
Record ID:
38761
Author(s):
Journal:
Publication Date:
June 14, 2022
Retraction Date:
August 26, 2022
(3.2 years years ago)
Subjects:
Institutions:
- Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea
- Department of Biomedical Sciences, Asan Medical Center, AMIST, University of Ulsan, College of Medicine, Seoul, South Korea
- Department of Convergence Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea
- Oncobix, Yongin, South Korea
- J2H Biotech, Suwon, South Korea
- Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea
- Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea
Country:
🇰🇷 South KoreaArticle Type:
Publisher:
American Association for Cancer Research
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1158/0008-5472.CAN-22-2507Citations (6)
6
Total Citations4
Post-Retraction(66.7%)
0
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
2
Within 1 year
1
After 2+ years
979
Days since retraction (latest)
Heavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and Challenges
Xiangmei Zhou, Liang Zeng, Zhe Huang et al. (8 authors)
Cancer Medicine
Open Access
Published: May 2025
1 citation
1 citation
979 days after retraction
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)
Zhinan Cheng, Hongwei Cui, Yaqi Wang et al. (10 authors)
Oncology Reports
Open Access
Published: Dec 2023
28 citations
28 citations
466 days after retraction
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Juan Bautista Blaquier, Sandra Ortiz‐Cuaran, Biagio Ricciuti et al. (6 authors)
Clinical Cancer Research
Published: Apr 2023
38 citations
38 citations
241 days after retraction
Discovery of Cyclopropane Sulfonamide Derivatives As a Potent Inhibitor of Egfr Against Mutation C797s
Wenyan Nie, Mengxuan Wang, Bing Xue et al. (14 authors)
Unknown Journal
Published: Jan 2023
128 days after retraction
Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer
Yun‐Jung Choi, Dasom Kim, Young Hoon Sung et al. (20 authors)
Cancer Research
Open Access
Published: Aug 2022
2 citations
2 citations
Same day as retraction
Quick Stats
Total Citations:
8
Years Since Retraction:
3.2 years
Open Access:
Yes
Last Checked:
Jul 24, 2025